Expert consensus provides support for transplanting HCV viremic organs into kidney, liver recipients

  • Burton JR & al.
  • Transplantation
  • 18 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A newly released consensus report supports use of transplanting organs from HCV viremic donors into many HCV-negative liver and kidney recipients.
  • Report was developed to address increasing numbers of younger, opioid overdose brain-dead HCV viremic donors but is broadly applicable.

Why this matters

  • Educate all potential recipients of risks, benefits associated with HCV viremic organs in transplantations.
  • Offer current candidates an opportunity to begin direct-acting antiviral (DAA) to potentially prevent or modify subsequent morbidity.

Key points

  • DAA treatment cures >95% of acute donor-derived HCV infection, supporting transplanting HCV viremic organs into HCV-negative recipients (as long as rigorous consent is obtained).
  • Access to preemptive pangenotypic DAA treatment is recommended in all liver, kidney recipients to reduce graft injury, chronic infection.
  • Carefully assess all medications for drug-drug interactions with DAA drugs.
  • Risk of HCV viremic transplantation should be weighed against risk of remaining on the transplant waiting list.
  • Risk of viral resistance-related allograft failure is low; consider transplantation in recipients failing DAA therapies.
  • Consider pretransplant liver biopsy in older donors aged ≥35 years to exclude advanced fibrosis; donor livers with Metavir >2 fibrosis (F)0-2 are acceptable for transplantation.